| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 22.05. | Fierce Pharma Asia-Merck-Kelun ADC's triple wins; Tools in China licensing deals; Takeda's $885M antitrust loss | ||
| 21.05. | ASCO: Merck, Kelun's sac-TMT ADC combo beats Keytruda by 65% on progression in first-line lung cancer | ||
| 21.05. | Lilly accuses church-linked pharmacies, wholesalers and more of running $200M+ rebate fraud scheme | ||
| 21.05. | Inside agency view: Ogilvy Health on AI's 'light speed,' nano influencers and the rise of Ria | ||
| 21.05. | Amgen's Tavneos, facing liver injury scrutiny, gets label update in Japan as patient starts resume | ||
| 21.05. | Gilead pledges 400K AmBiosome doses to fight visceral leishmaniasis in expanded WHO collab | ||
| 21.05. | With Voxzogo under pressure, BioMarin touts trial win in label expansion bid | ||
| 20.05. | BMS taps Anthropic's Claude for enterprise-wide AI adoption to speed R&D, global workflows | ||
| 20.05. | CG Life appoints Collette Douaihy as chief creative officer as C-suite buildout continues | ||
| 20.05. | Amgen, bidding adieu to CFO, lures Galderma exec with hefty $12.4M bonus | ||
| 20.05. | Gilead inks another deal with Korean API manufacturer Yuhan, this time worth $140M | ||
| 20.05. | Tarsus taps John Cena for its latest Demodex blepharitis campaign | ||
| 19.05. | Roche signs generic Xofluza licensing deal with Medicines Patent Pool for 129 countries | ||
| 19.05. | UCB digs deeper into Bimzelx's psoriatic arthritis win over Skyrizi | ||
| 19.05. | White House adds 600 generic meds to TrumpRx purchasing portal | ||
| 19.05. | Takeda slapped with $885M verdict in pay-for-delay antitrust case | ||
| 18.05. | Novartis terminates plant contract with Chinese CDMO Porton, threatens $64M in legal claims | ||
| 18.05. | Supreme Court declines to hear IRA challenges from Novo, AstraZeneca and more | ||
| 18.05. | Eli Lilly teams up with Caitlin Clark to bounce sports courts into Indianapolis neighborhoods | ||
| 18.05. | AstraZeneca notches key FDA nod in hypertension, with an approval sweetener for Fasenra too | ||
| 18.05. | Merck, Kelun score with sac-TMT in endometrial cancer trial | ||
| 18.05. | Bristol Myers looks at Houston for potential $1B manufacturing plant | ||
| 18.05. | Daiichi, AstraZeneca's Enhertu breaks into early breast cancer with dual FDA approvals | ||
| 15.05. | Roche's ctDNA-guided approach in post-surgical bladder cancer pays off with Tecentriq nod | ||
| 15.05. | After Makary departure, CDER chief Tracy Beth Hoeeg likely headed out at FDA: report |